TAKE THIS POLL |
|
|
- GSK plans to enter generics market 23 Jul 2008 19:20 GMT
... to boost sales in emerging markets. The pharmaceuticals group has negotiated first right of refusal ... its profits from just two medicines – Advair and Avandia – and second quarter results ... would open up its pipeline of experimental drugs to external scrutiny by venture capitalists and healthcare players ...
- GlaxoSmithKline Q2 Net Profit Rises 23 Jul 2008 16:54 GMT
... 4% to GBP1.38 billion. Total sales of Seretide/Advair, for asthma and COPD, were up 6% ... noted that the use of Advair for treatment of COPD continues to grow, and in ... sales. During the quarter, sales of anticonvulsant drug Lamictal grew 18% to GBP323 million and ...
- GSK restructures R&D to boost pipeline 23 Jul 2008 13:53 GMT
... as would be the case with a biotechnology company. The purse strings will be held ... incentives linked to the success of any drugs they develop. Witty is also planning to test ... areas for the group. GSK's asthma drug Seretide/Advair saw sales up 6% to £964m. Vaccine ...
- We must diversify, says new Glaxo boss 23 Jul 2008 13:31 GMT
... new head of GlaxoSmithKline today said the drug giant must change to survive the growing ... £5.87bn (€7.4bn) after lower sales of diabetes treatment Avandia - hit by a health scare ... to deteriorate." GSK's biggest seller, asthma drug Seretide/Advair saw a 6% rise to sales to ...
- Glaxo to invest in diversity 23 Jul 2008 12:52 GMT
... meagre rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ... grim outlook for conventional, or small molecule, pharmaceuticals, where a barrage of looming patent expiries ...
- New Glaxo chief wants broader, lower-cost company 23 Jul 2008 12:36 GMT
... plans to make the world's second largest drugmaker a broader business with lower costs, but ... and consumer products offset tough trading in pharmaceuticals. But the group kept its full-year forecast ... rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ...
- Glaxo to invest in diversity, cautious on outlook 23 Jul 2008 12:30 GMT
... plans to make the world's second largest drugmaker a broader business with lower costs, but ... and consumer products offset tough trading in pharmaceuticals. But the group kept its full-year forecast ... rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ...
- Glaxo chief wants broader group 23 Jul 2008 12:19 GMT
... meagre rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ... grim outlook for conventional, or small molecule, pharmaceuticals, where a barrage of looming patent expiries ...
- Glaxo Earnings Rise 13%, Cautious on Outlook 23 Jul 2008 11:51 GMT
... his three priorities were diversification, smarter value-based drug research and a simplification of operating systems. He ... and consumer products offset tough trading in pharmaceuticals. But the group kept its full-year forecast ... rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ...
- MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Med 23 Jul 2008 11:50 GMT
... MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, ... he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project ... clinical development of inhaled corticosteroids for the treatment of asthma in his role as project ...
- Glaxo CEO wants broader group, cautious on outlook 23 Jul 2008 11:50 GMT
... plans to make the world's second largest drugmaker a broader business with lower costs, but ... and consumer products offset tough trading in pharmaceuticals. But the group kept its full-year forecast ... rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ...
- UPDATE 1-Glaxo CEO wants broader group, cautious on outlook 23 Jul 2008 11:50 GMT
... plans to make the world's second largest drugmaker a broader business with lower costs, but ... and consumer products offset tough trading in pharmaceuticals. But the group kept its full-year forecast ... rise in sales of its top-selling drug, Advair for asthma. "It's clear that key growth ...
- MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs 23 Jul 2008 11:35 GMT
... MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP ... he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project ... clinical development of inhaled corticosteroids for the treatment of asthma in his role as project ...
- Waiting for a Witty response to drug firm's hard times 21 Jul 2008 09:17 GMT
... Waiting for a Witty response to drug firm's hard times THE half-year results season ... and falling sales for its under-fire diabetes treatment Avandia, GSK is in the throes of ... other products - such as asthma treatment Advair. “We expect GlaxoSmithKline to report a mixed ...
- GSK and Rolls in spotlight as half-year results due 21 Jul 2008 09:15 GMT
... the role at the world's second biggest drugs company at a time of change for ... and falling sales for its under-fire diabetes treatment Avandia, GSK is in the throes of ... other products - such as asthma treatment Advair. “We expect GlaxoSmithKline to report a mixed ...
- US to help India on drug regulation 20 Jul 2008 20:50 GMT
... New Delhi: India’s drug regulator is collaborating with its US counterpart to ... said D.G. Shah, secretary general of Indian Pharmaceutical Alliance, an industry lobby that represents big ... Avandia, a diabetes drug, and asthma medicine Advair, both from GlaxoSmithKline Plc. and arthritis drug ...
1 - 25 of 51 next >
News by PR Newswire
|
